Clinical trial
A Phase I Study to Evaluate the Safety and Pharmacokinetics of ABBV-399 in Japanese Subjects With Advanced Solid Tumors
NCT03311477 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Safety and Pharmacokinetics of ABBV-399 in Japanese Subjects With Advanced Solid Tumors
- Lead sponsor
- AbbVie
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 6, 2017
- Completion date
- March 4, 2019
- Enrollment
- 9 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors cancer